Geneception Cell & Gene Therapy development, China

Breakthrough gene and cell therapies

Geneception is an innovation-driven biopharmaceutical company focused on the development of breakthrough gene and cell therapies. Established in US, its aim is to become a market leader in the Gene and Cell Therapy industry. Geneception will be among a handful of companies in China to possess whole production chain capability from early research to commercial production.

Geneception began expanding its China business footprint in 2019. The company planned two developments in Shanghai and Hangzhou.  PM Group provided procurement and CM services for the initial project (Phase 1A) in Shanghai. Following its successful completion, we were subsequently awarded EPCMCQ services for the Phase 1B project involving a 6,000sqm viral vector facility in Hangzhou.

Work commenced in Hangzhou in the second half of 2020 and mechanical completion was achieved following an intensive four month construction phase.

"We are delighted to have had the opportunity to work with Geneception on both projects,” said Felix Ni, Managing Director, PM Group – China.  "Achieving mechanical completion following four months of construction is an excellent achievement by the whole team. It was accomplished with great commitment by our client and project partners to schedule, cost and quality. Congratulations to our client and to the whole team and many thanks to everyone who worked on this project".